Case Report
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 28, 2015; 21(8): 2568-2572
Published online Feb 28, 2015. doi: 10.3748/wjg.v21.i8.2568
Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy
Jung Gil Park, Soo Young Park, Hye Won Lee
Jung Gil Park, Division of Gastroenterology and Hepatology, Department of Internal Medicine, CHA University, Gumi CHA Medical Center, Gumi 730-728, South Korea
Soo Young Park, Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu 700-721, South Korea
Hye Won Lee, Department of Pathology, School of Medicine, Kyungpook National University, Daegu 700-721, South Korea
Author contributions: Park JG designed the report and collected the patient’s clinical data; Park SY performed the radiofrequency ablation; Lee HW analyzed histology and created histologic figure; Park JG and Park SY wrote the paper.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Soo Young Park, MD, PhD, Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Kyungpook National University, 130 Dongdeok-ro, Jung-gu, Daegu 700-721, South Korea. psyoung0419@gmail.com
Telephone: +82-53-2005519 Fax: +82-53-4268773
Received: September 14, 2014
Peer-review started: September 15, 2014
First decision: October 14, 2014
Revised: October 18, 2014
Accepted: November 11, 2014
Article in press: November 11, 2014
Published online: February 28, 2015
Processing time: 166 Days and 18.7 Hours
Core Tip

Core tip: Though sorafenib is well known to efficacy in advanced hepatocellular carcinoma (HCC), the consensus of its role as down-staging is limited. Depending on response after sorafenib therapy, active strategy should be needed to offer chance for cure in advanced stage HCC.